On May 18th, the People’s Vaccine Alliance sent Justin Trudeau, Prime Minister of Canada, a letter urgently requesting that vaccines, therapeutics and diagnostics for COVID-19 be added to Schedule 1 of the Patent Act. Below is the text of the PVA… Continue Reading
Brief to Standing Committee on International Trade and Investment Policy: Selected Consideration Concerning COVID-19 Vaccines Knowledge Ecology International James Love and Arianna Schouten 30 April 2021 This brief will discuss (1) the scope and purpose of the proposed World Trade… Continue Reading
On April 27th, a letter signed by 41 Canadian experts was sent to the Prime Minister of Canada, the Minister of Innovation, Science & Industry, and the Minister of Health. The letter requests the amendment of Schedule 1 of the… Continue Reading
In Canada, the foreground intellectual property arising under procurement contracts by default belongs to the contractor. However, there are several exceptions to this rule. One key policy provision allows the government to claim title of the foreground intellectual property “where…… Continue Reading
In its 2018 Special 301 submission, PhRMA targets a number of countries for pricing and reimbursement policies deemed hostile to the pharmaceutical industry. Among these, PhRMA strategically lobbies for the strongest classifications for Canada and Korea — countries dealing with… Continue Reading
The 2012 USTR Special 301 Report was published on April 30, 2012. The report details USTR’s unilateral standards for the granting and enforcement for a diverse set of intellectual property rights, and singles out countries that USTR claims do not… Continue Reading